BioMarin asserts patent infringement claims against Dr. Reddy's Laboratories related to Kuvan®
Clients BioMarin Pharmaceutical Inc.
Jones Day represented BioMarin Pharmaceutical, Inc. in a patent infringement action against Dr. Reddy's Laboratories relating to the defendant's submission of an Abbreviated New Drug Application to the FDA seeking approval of a generic versions of Kuvan® (sapropterin dihydrochloride), the only FDA-approved treatment to reduce blood phenylalanine levels in persons with BH-4 responsive phenylketonuria (PKU). A settlement was reaches and the case dismissed.
BioMarin Pharmaceutical Inc. et al. v. Dr. Reddy's Laboratories, Inc. et al., Case No. 3:14-cv-07203 (D.N.J.)